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Abstract 
Background: Atopic dermatitis is the first clinical manifestation of the atopic march, with the highest incidence 
in the first year of life. Those affected often go on to develop other allergic diseases including food allergy, asthma, 
and allergic rhinitis. Recent evidence suggests that sensitization to foods may occur through a defective skin barrier 
which is common in atopic dermatitis in early life. We hypothesize that therapeutic aggressive intervention to treat 
new onset atopic dermatitis may prevent the development of later allergen sensitization, and associated food allergy, 
asthma, and allergic rhinitis.
Methods: This study is a multi‑center, pragmatic, two‑parallel group, assessor‑blind, superiority, individually ran‑
domized controlled trial. Atopic dermatitis infants (N = 650) 7–13 weeks old who develop an itchy rash within the 
previous 28 days are randomly assigned to the aggressive treatment or the conventional treatment in a 1:1 ratio. The 
primary outcome is oral food challenge‑proven IgE‑mediated hen’s egg allergy at the age of 28 weeks.
Discussion: This is a novel pragmatic RCT study to examine the efficacy of early aggressive treatment for atopic der‑
matitis to prevent later food allergy. If our hypothesis is correct, we hope that such a strategy might impact on disease 
prevention in countries where food allergy is common, and that our results might reduce the frequency and associ‑
ated costs of all food allergies as well as hens egg food allergy. Long‑term follow and other similar studies will help 
to determine whether such a strategy will reduce the burden of other allergic diseases such as asthma and allergic 
rhinitis.
Trial registration UMIN‑CTR: UMIN000028043
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Background
A systematic review of international trends in atopic 
dermatitis (AD) suggested that the prevalence of AD is 
increasing in Africa, eastern Asia, western Europe, and 
parts of northern Europe (e.g., the UK) [1]. According to 
a Japanese national survey, the prevalence of infants at 
the age of 6  months with AD or a suspected history of 
AD was about 25% [2].
The prevalence of food allergy (FA) has been increasing 
worldwide as well [3]. In Japan the most common food 
allergen was hen’s egg and the second most common was 
cow’s milk [4]. A general cohort study in Tokyo reported 
that the cumulative incidence of FA and hen’s egg allergy 
was 9% and 5.1%, respectively, among children aged 
12 months [5].
Additionally, 50.8% of infants (95% CI 42.8, 58.9) with 
early AD onset (< 3  months old) who required doctor-
prescribed topical corticosteroid treatment, who were 
more likely to be severe AD, developed challenge-proven 
FA [6]. Shoda et al. [5] demonstrated that in each age (by 
month) stratum, infants with onset of eczema within the 
first 1–2 months after birth had the highest risk of FA at 
3  years of age (aOR 6.61; 95% CI 3.27, 13.34; p < 0.001) 
and the second highest was within 3–4  months after 
birth (aOR 4.69; 95% CI 2.17, 10.13). The results from 
previous studies [5, 6] suggest that infants who develop 
AD in early infancy have a higher risk for FA.
The allergic march describes the development of AD 
and concomitant sensitization to food and aeroallergens 
in early childhood, progressing to asthma and allergic 
rhinitis in later childhood or adult life [7]. A European 
cohort study noted that both early transient and early 
persistent AD increased the risk of food allergy at aged 6 
(aOR 3.69; 95% CI 1.93, 7.035, and aOR 7.08; 95% CI 3.59, 
13.975, respectively) [8]. In particular, early persistent 
AD increased the risk of asthma (aOR 2.87; 95% CI 1.31, 
6.315), allergic rhinitis (aOR 4.04; 95% CI 1.82, 8.955) and 
sensitization to nhalant allergens (aOR 3.36; 95% CI 1.78, 
6.355) at aged 6. Martin et  al. [6] reported that 20% of 
1-year-old infants who had a history of eczema received 
a diagnosis of FA.
Lack et  al. [9] suggested the dual-allergen-exposure 
hypothesis which states that tolerance is induced from 
oral exposure to food antigen, enhancing immune 
response to suppress allergy and that infants with eczema 
are exposed to food antigen via skin and induce immune 
cells, enhancing allergy and producing IgE antibodies 
(sensitization). This hypothesis implies that it is impor-
tant not only to induce oral immune tolerance, but to 
prevent allergic sensitization through the skin to reduce 
allergies. Inflammation of the skin and allergic sensi-
tization is suggested as a mechanism of AD. Lack et  al. 
[10] demonstrated that peanut allergy was positively 
associated with the use of skin care products containing 
peanut oil in England. The results from the study sug-
gested that peanut allergens absorbed through the skin 
may cause allergic sensitization.
Topical corticosteroids (TCSs) and tacrolimus oint-
ments are the mainstream of pharmacotherapy to 
suppress skin inflammation associated with AD. The 
approach for using TCSs in AD is either reactive or proac-
tive management [11, 12]. Reactive management is when 
TCSs are administered only when the rash worsens. Pro-
active management is applying anti-inflammatory TCS 
therapy intermittently even after the skin clears to sup-
press subclinical inflammation of the skin in AD patients. 
Fukuie et al. [13] performed a 2-year retrospective cohort 
study of patients with moderate to severe AD to investi-
gate whether proactive management changes serum IgE 
level compared to reactive management. Serum total IgE 
titer was significantly decreased in the proactive treat-
ment group compared with the reactive treatment group 
(2442  IU/mL vs. 2081  IU/mL; p < 0.01). In addition, the 
serum egg white-specific IgE level decreased significantly 
during follow-up (60.0 IU/mL vs. 36.6 IU/mL; p = 0.004). 
In a case control study, infants with early proactive 
management (beginning at ≤ 4  months old) had a lower 
prevalence of egg allergy compared to infants with later 
proactive management (beginning at ≥ 5  months) at the 
age of 18 months (9.1% vs. 24.2%) [14]. Previously pub-
lished results suggest that proactive management might 
be effective for reducing eczema flare-ups, and for pre-
venting development of allergic sensitization. Thus, early 
proactive management for infantile AD may reduce the 
risk of FA.
Natsume et al. [15] conducted a double-blind, placebo-
controlled RCT (PETIT Study) for infants 4–5  months 
of age with eczema who were enrolled and randomly 
assigned to the early introduction of egg or placebo 
to examine the proportion of participants with hen’s 
egg allergy confirmed by open oral food challenges at 
12 months of age. In the study, 121 participants revealed 
that the prevalence of egg allergy was 37.7% in the pla-
cebo group (n = 61) and 8.3% in the egg group (n = 60), 
and the risk ratio was 0.221 (95% CI 0.090, 0.543; 
p = 0.00013); this demonstrated that the prevalence in the 
egg group was significantly lower than that in the placebo 
group. Especially, there were “zero” infants with hen’s egg 
allergy at 12 months of age among the infants who were 
not sensitize to hen’s egg at entry of the study. Immune 
tolerance is not considered to be induced merely by orally 
taking allergenic foods from the early stage of infancy.
Looking at allergic march, AD is the first clinical mani-
festation with the highest incidence in the first year of life 
and those affected develop other allergic diseases such 
as FA, asthma, and allergic rhinitis later in childhood in 
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most patients. We think that it is important not only to 
introduce oral immune tolerance by early hen’s egg con-
sumption, but to prevent sensitization via skin to prevent 
the development of FA. We hypothesize that to prevent 
future allergic march, an appropriate intervention for 
AD, which emerges at the first stage of allergic march, is 
important to be considered. We expect that early aggres-
sive intervention with proactive method for AD will 
likely prevent development of later allergen sensitization, 
FA, asthma, and allergic rhinitis. The main purpose is to 
test by a randomized controlled trial the superiority of 
aggressive intervention over conventional treatment of 
infantile AD to prevent FA.
Methods/design
This study is a multi-center, pragmatic, two-parallel 
group, assessor-blind, superiority, individually rand-
omized controlled trial (Fig. 1). The study intervention is 
continued until participants become 6  months old. Pri-
mary endpoint is assessed at the time when participants 
become 6 months old.
Setting
The study is recruiting infants with atopic dermatitis 
across Japan. Investigational sites include tertiary care 
centers that are found in the acknowledgement.
Participants
Infants with AD (N = 650) who meet all of the following 
inclusion criteria and none of the exclusion criteria will 
be enrolled in PACI Study.
Inclusion criteria
Infants must meet the following criteria to be enrolled in 
the study:
1. Infants (7–13 weeks old) who develop an itchy rash 
within the previous 28  days and receive a diagnosis 
of AD based on the under 4 years old version of the 
U.K. Working Party’s diagnostic criteria [16–18].
Exclusion criteria
Infants who meet any of the following will be excluded 
from the study:
 1. Infants born before 37 weeks of gestation
 2. Twin or multiple
 3. History of emollient (heparinoid cream:  Hirudoid® 
Soft ointment) and TCSs (alclometasone dipro-
pionate:  Almeta®; betamethasone valerate: 
 Rinderon®-V; mometasone furoate:  Fulumeta®) 
side effects
 4. History of taking oral or intravenous steroids 
within the previous 28 days
Infants with atopic dermatitis at the age of 7–13 weeks
N=650
Aggressive intervention group, n=325
Early aggressive treatment with topical 
corticosteroids
(Proactive method)
Conventional treatment group, n=325
Standard treatment based on clinical practice 
guidelines for the management of atopic dermatitis 
2016 1
(Reactive method)
Registration and Randomization
Fig. 1 Trial scheme
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 5. History of taking immunosuppressive agents 
(cyclosporine, tacrolimus, and so forth) or biolog-
ics, except vaccinations or intravenous immuno-
globulins, within the previous 28 days
 6. IgE-mediated hen’s egg allergy
 7. Infants whose immediate family plans to move 
and who may not be able to visit the study site at 
28 weeks of age
 8. Parents unable to understand Japanese
 9. Unwillingness to adhere to the study requirements 
and procedures
 10. Infants with severe disease and other skin diseases 
that affect dermatological evaluation and study 
physicians judge that they are not appropriate for 
study participation
Interventions
Participants apply the emollients and TCSs described 
below as study drugs.
Emollients: Heparinoid cream  (Hirudoid® Soft 
ointment)
TCSs: Alclometasone dipropionate  (Almeta®), beta-
methasone valerate  (Rinderon®-V), and mometasone 
furoate  (Fulumeta®)
Participants in aggressive intervention group obtain 
Early aggressive treatments with topical corticoster-
oids (proactive method). Hanifin et  al. [19] performed 
an RCT for participants who were at least 3 months old 
and who had moderate or severe AD, to examine the effi-
cacy of proactive therapy. Early aggressive treatments 
are modified from the Hanifin et  al. study intervention, 
and details are described in Additional file  1. On the 
other hand, participants in conventional treatment group 
obtain standard treatment based on the Guidelines for 
the Management of Atopic Dermatitis (2016) [20] (Step-
up reactive method). Standard treatment is based on the 
Guidelines for the Management of Atopic Dermatitis 
(2016) [20], and the details are described in Additional 
file 1.
Aggressive intervention group
Basic whole‑body treatment
Participants will be followed as described below and 
administered basic whole-body treatment, except for 
scalp.
Emollients
Whole body except scalp
Registration day (Day 0) of the 
study to 28 weeks of age
Hirudoid® Soft ointment every day 
twice a day
Topical corticosteroids
Face Body except scalp and face
Registration 
day (Day 0) 
to Day 14 of 
the study
Almeta® oint‑
ment every 
day twice a 
day
Rinderon®‑V ointment every day 
twice a day
Day 15 of the 
study to 
28 weeks of 
age
Almeta® oint‑
ment two 
days per week 
twice a day
Rinderon®‑V ointment 2 days per 
week twice a day
Additional skin rash treatment
Participants are to apply TCSs as additional treatment as 
described below:
Face Body except scalp 
and face
Scalp
Day 15 of the study to 
28 weeks of age
Day 15 of the study to 
28 weeks of age
Day 15 of the 
study to 
28 weeks of 
age
Almeta® ointment every 
day until rash remission 
twice daily
Rinderon®‑V ointment 
every day until rash 
remission twice a day
Rinderon®‑V 
lotion until 
rash remission 
twice a day
Conventional treatment group
Basic whole‑body treatment
Participants will be followed as described below and 
administered basic whole-body treatment, except for 
scalp.
Whole body except scalp
Registration day (Day 0) of the 
study to 28 weeks of age
Hirudoid® Soft ointment every day 
twice a day
Additional skin rash treatment
Participants are to apply TCSs as additional treatment as 
described below:
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Area Face Body except scalp and face Scalp
Severity of skin 
rash
Less mild Mild, moderate, 
and severe
Less mild Mild and moderate Severe Any severity
Registration day 
(Day 0) of the 
study to 28 weeks 
of age
Without 
additional 
treatment
Almeta® ointment 
every day until rash 
remission once 
a day
Without 
additional 
treatment
Almeta® ointment every 
day until rash remission 
once a day
Rinderon®‑V oint‑
ment every day 
until rash remission 
once a day
Rinderon®‑V lotion 
until rash remission 
once a day
Proxies (parents or legal guardians) of the participants 
will be taught how to use the TCSs and the emollient 
for their infants in each group by a study physician with 
video lectures and skin care leaflets. Nutritional educa-
tion for participants will also be given on the day of study 
registration.
It is recommended to introduce solid food to infants 
at 4–5  months of age. Breastfeeding is encouraged to 
continue until at least 6  months of age. Mothers who 
are breastfeeding are not restricted from ingesting hen’s 
egg. Participants are not permitted to eat hen’s egg until 
the oral food challenge test at the age of 28  weeks is 
completed.
Primary outcome
Primary outcome is a presence of oral food challenge-
proven IgE-mediated hen’s egg allergy at the age of 
28  weeks because hen’s egg is the most common causal 
FA in Japan.
The timing of oral food challenge tests for hen’s egg is 
set at the age of 28 weeks because we decided to make a 
recommendation for participants in our study to ingest 
hen’s egg starting at 6  months of age based on the past 
study results reported by PETIT Study [15].
Secondary outcomes
Efficacy endpoints include the following:
 1. Food challenge test scores [21] at the age of 
28 weeks
 2. Total IgE antibody titre in serum at the age of 
28 weeks
 3. Egg white, ovomucoid, milk, soy, wheat, and pea-
nut-specific IgE antibody titers in serum at the age 
of 28 weeks
 4. Egg white, ovomucoid, milk, soy, wheat, and pea-
nut-specific IgG4 antibody titers in serum at the 
age of 28 weeks
 5. Eczema Area and Severity Index (EASI) scores [22] 
at 2, 4, and 8 weeks after study entry and at the age 
of 28 weeks
 6. Patient Oriented Eczema Measure (POEM) scores 
[23] weekly through the study
 7. Percentage of disease-free days throughout the 
study
 8. Dose of rescue medication used throughout the 
duration of the study
 9. Infants’ Dermatitis Quality of Life Questionnaire 
(IDQoL) [24, 25] at 2, 4, and 8  weeks after study 
entry and at 28 weeks of age
 10. Family Impact of Childhood Eczema Questionnaire 
(DFI) [26] at 2, 4, and 8 weeks after study entry and 
at 28 weeks of age
 11. Cumulative incidence of IgE-mediated FA assessed 
by a doctor’s interview during the study
 12. Cumulative incidence of wheezing assessed by 
a doctor’s interview during the study (parental 
reports evaluated by doctor)
Safety endpoints include the following:
1. Serious adverse events
2. Adverse drug reactions
3. Salivary cortisol concentrations at 2, 4, and 8 weeks 
after study entry and at the age of 28 weeks
4. Body weight and body height at the age of 28 weeks
Adherence endpoints include the following:
1. TCS adherence index in accordance with the protocol
2. Dose of TCS used during the study
Study procedures
This study uses VIEDOC™ selected as the Electronic 
Data Capture system (EDC) by Pharma Consult-
ing Group Japan K.K. to register and allocate partici-
pants and perform data collection. Study physicians 
confirm eligibility criteria. Based on the result of the 
confirmation of eligibility criteria, study physicians 
obtain informed consent for study participation using 
a fixed document request from the proxy (parent or 
legal guardian) of the participants who meet all of the 
inclusion criteria and none of the exclusion criteria. 
Stratified block assignment with the number of weeks 
after birth (7–10 weeks, 11–13 weeks) as the factor in 
the order of registration is performed and participants 
are randomly assigned to the “aggressive intervention 
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Table 1 Assessment schedule
Study treatment start Study period
Visit 1 2 3 4 5
Time point
Entry
(Day 0)
2 weeks 
after entry
(Day 14)
4 weeks 
after 
entry
(Day 28)
8 weeks 
after 
entry
(Day 56)
28 weeks of 
age
Visit windows ±6 days ±7 days ±7 days ±14 days
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
Aggressive intervention
Convention intervention
Skincare education X
Nutrition education X
ASSESSMENTS:
Background information X
Nutrition X X X X X
Living environment X X X X X
Body height X X X X X
Body weight X X X X X
Oral food challenge test21
(hen’s egg)
X
IgE-mediated FA by interview X X X X X
Wheeze X X X X X
Total IgE, egg white, 
ovomucoid, milk, wheat soy, 
peanut, and Ara h2-specific IgE 
and IgG4 antibodies in serum
X X
EASI 38 by blinded physician X X X X X
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group” or “conventional treatment group” in a ratio 
of 1:1 using EDC system (VIEDOC™). Randomiza-
tion sequence is generated by VIEDOC™. Earlier the 
onset of eczema is, higher the incidence of food allergy 
becomes in later life [5, 6], so the number of weeks 
after birth was assigned as a stratification factor. Study 
assessment schedule is shown in Table  1. Food chal-
lenge test (hen’s egg) is open method to participants 
and their caregivers and assessed by blinded physician, 
who do not know participants’ group assigned nor give 
treatment to them, at the age of 28 weeks. Pasteurized 
low egg powder 2.6  g (whole egg 10.4  g, egg protein 
1.2 g) is given. Participants eat 0.1–0.5–2 g of the pas-
teurized egg powder every 40 min. The challenge tests 
are evaluated based on the PRACTALL criteria [21],
Participants, parents, and investigators who treat par-
ticipants with AD are not blinded to the study interven-
tion. The physicians who perform OFC and examine 
EASI are blinded to the group allocations. Those who are 
blinded to the study intervention are required to meet 
the following criteria.
1. Blinded physicians are not the physicians who treat 
participants in the PACI Study.
2. Blinded physicians do not look at documents and all 
other information about the study intervention.
Study physicians obtain the most recent information 
about the study medicines  (Hirudoid® Soft ointment, 
 Almeta®,  Rinderon®-V, and  Fulumeta®) from their pack-
age inserts. We evaluate adverse drug reaction. Par-
ticipants can discontinue the study if participants have 
adverse events (see 5.9.2 STUDY DISCONTINUATION 
on Additional file 1).
Sample size calculation
Palmer et al. [27] performed a double-blind, randomized 
controlled trial for infants with AD to test whether or not 
one-sixth of a raw whole egg taken every day can prevent 
development of IgE-mediated egg allergy. The infants 
were allocated to receive 1 teaspoon of pasteurized raw 
whole egg powder (n = 49) or rice powder (n = 37) daily 
from 4 to 8  months of age. A high proportion (31% 
Table 1 (continued)
Study treatment start Study period
POEM39 by caregivers ✔ ✔
Disease-free days of AD X X X X
Amount of emollients and TCSs 
including rescue medication
usage
X X X X
Days of applying emollients 
and TCSs including rescue 
medication usage
X X X X
IDQoL 40 41 and DFI scores42 X X X X X
Salivary cortisol X X X X
Concomitant therapy X X X X X
Adverse events X X X X
Amount of emollients and TCSs 
used
X X X X
Daily
Every week
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[15/49]) of infants randomized to receive egg had an 
allergic reaction to the egg powder and 20% (10/49) had 
a reaction at the first ingestion of egg powder (one-sixth 
of a raw whole egg) at 4 months of age. When the con-
trol group participants received half of a raw egg provo-
cation test at 12  months, 51% (18/35) were diagnosed 
with IgE-mediated egg allergy. These data suggested that 
prevalence of egg allergy in infancy is likely to depend 
on the provocation dose of egg and the preparation of 
egg such as heated or raw, and also on age and race of 
the participant. Therefore, we estimate that at least 30% 
of the participants in the conventional treatment group 
in this study will be diagnosed with IgE-mediated hen’s 
egg allergy using an oral food challenge test at the age of 
28 weeks. However, the prevalence of IgE-mediated hen’s 
egg allergy among infants treated with early aggressive 
intervention for AD has never been reported. In Japan, 
it is common that infants at the age of 28 weeks have not 
eaten hen’s eggs, and the prevalence of hen’s egg allergy 
at the age of 28 weeks in Japan is unclear. We consider a 
clinically effective prevalence of infants with early aggres-
sive intervention for AD to be 20%. For sample size cal-
culation, the proportion of egg allergy in early aggressive 
intervention and conventional treatment groups are esti-
mated to be 20% and 30%, respectively. With a one-sided 
significance level of 0.025, 581 participants are needed 
to provide 80% statistical power. One interim analysis 
examining efficacy is planned when almost half the par-
ticipants are finished their trial assessment. Considering 
the interim analysis, 614 participants are needed. We 
expect a drop of about 5% and set the target number of 
study participants to 650.
Statistical analysis
Statistical analysis will be performed following the inten-
tion to treat (ITT) principle, where participants will 
be analyzed as they were randomized, not as they were 
treated. The primary analysis is performed using full 
analysis set (FAS), and secondarily using per protocol 
set (PPS). The participants who have missing data for the 
presence of IgE-mediated hen’s egg allergy are defined 
as having IgE-mediated hen’s egg allergy and included 
in the FAS analysis. The participants who have missing 
data for the presence of IgE-mediated hen’s egg allergy 
are excluded from the PPS analysis. To verify the study 
hypothesis, “the aggressive intervention group has lower 
prevalence of IgE-mediated hen’s egg allergy compared to 
the conventional treatment group”, the main comparison 
is the null hypothesis that the percentage of IgE-mediated 
hen’s egg allergy is higher in the aggressive treatment 
group than in the conventional group” and the alternative 
hypothesis is that the percentage of IgE-mediated hen’s 
egg allergy is lower in the aggressive treatment group 
than in the conventional group. The p value is calculated 
by the difference in percentage with a one-sided test. 
The significance level is 0.025. The difference and ratio 
of these proportions and their 95% confidence intervals 
for each intervention group will also be calculated. All 
secondary endpoints will be analyzed using FAS and sec-
ondarily using PPS. The details of statistical methods are 
described in the statistical analysis plan.
Interim analysis is conducted with the aim of prevent-
ing disadvantages to participants due to excessive efficacy 
procedures unintended in study treatment. The interim 
analysis is performed when almost half of the partici-
pants finish their assessments for the primary endpoint. 
The interim analysis is done for primary endpoint and 
safety endpoints. The study registration for study par-
ticipants does not stop while conducting the interim 
analysis. The analysis of primary endpoint is performed 
along with the primary endpoints analysis. The stop-
ping boundary for the analysis of primary endpoint will 
be calculated based on the O’Brien–Fleming type with 
a Lan–DeMets α and βspending function at the actual 
information time. For example, the significance levels of 
effective discontinuation and invalid discontinuation are 
0.0015 and 0.2883, respectively, with the interim analy-
sis for 307 participants who are half of the planned study 
participants. The interim analysis is conducted by a trial 
statistician of the interim analysis under a closed situa-
tion. The statistician prepares a report of interim analysis 
results and submits it to the independent data monitor-
ing committee. The results of the interim analysis will be 
evaluated by the members of the independent data moni-
toring committee to investigate whether or not the study 
continues, and the investigation result report is submit-
ted to the principle investigator.
Monitoring and ethics
This study follows the Declaration of Helsinki Ethical 
Principles for Medical Research Involving Human Sub-
jects and the Ethical Guidelines for Medical and Health 
Research Involving Human Subjects (2014 December 22, 
the Japanese Ministry of Education, Ministry of Health, 
Labour and Welfare Notification No. 3). PACI Study 
has been approved by IRB of National Center for Child 
Health and Development (No. 1347) and each investiga-
tional site. Details are described in Additional file 1.
Discussion
Potential benefits of study
To our knowledge, this would be the first pragmatic RCT 
study to examine the efficacy of early aggressive interven-
tion for AD to prevent later FA. If we establish a novel 
new strategy for prevention of FA development by early 
aggressive intervention for AD, it is expected that quality 
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of life in patients will improve, the prevalence of FA will 
decrease, and the medical care cost will be reduced. In 
addition, we are doing follow-up cohort study, PACI-On 
Study, after the PACI Study. We will observe the partici-
pants until they reach to 6 years old. From the results of 
the PACI-On Study, we will reveal that natural course of 
allergic diseases could be changed by this early aggressive 
intervention.
Potential study harms
Although we use TCSs approved officially in daily basis, 
we should consider the safety of TCSs. TCSs are topi-
cal anti-inflammatory agents and they are safer than 
systemic steroids administered via an oral or intrave-
nous route. Absorption of TCS in the skin is considered 
to depend on many factors such as molecular weight 
of TCS, cream or ointment bases, application amount, 
potency of TCS, application period, and age. Cutaneous 
side effects include telangiectasias, skin atrophy, skin 
striae, focal hypertrichosis, acne-like eruptions, rosacea-
like eruptions, folliculitis, and so forth [28, 29]. In an 
observational study in the US, children with moderate 
or severe AD did not show adrenal suppression although 
they had used TCSs for more than several years since 
infancy [30]. Fukuie et  al. [19] performed rapid ACTH 
stimulation tests for eight children in the proactive group 
and four children in the reactive group at 3 months after 
starting the study intervention and found that no chil-
dren showed adrenal suppression. However, Hanifin et al. 
[31] demonstrated that 2/44 children in the proactive 
group had adrenal suppression in the RCT. Children are 
more susceptible to steroids than adults and, therefore, 
their treatment should be carefully considered.
Other similar studies
Looking into prevention of AD by moisturizer, two ran-
domized controlled trials (RCTs) were performed to 
investigate whether protecting the skin barrier with a 
moisturizer applied at the beginning of the neonatal 
period would prevent development of infantile AD. These 
studies demonstrated that application of a moisturizer 
during early life reduced the incidence of AD/eczema in 
infants [32, 33]. However, the studies could not confirm 
the efficacy of food allergy prevention. However, BEEP 
Study is ongoing RCT in the UK to investigate whether 
daily application of emollients for the first year of life can 
prevent not only AD, but FA and asthma developing in 
high-risk infants [34]. BEEP Study will validate the effi-
cacy of emollients for prevention of FA in the future. Pre-
ventADALL study is also ongoing, a 2 × 2 factorial, RCT 
to examine the efficacy of primary prevention of allergic 
diseases such as atopic dermatitis and food allergy by reg-
ular intake of six-food-items from 3  months of age and 
emollient in general populations of Norway and Sweden 
[35]. Shimojo et  al. conducted a 2 × 2 factorial RCT to 
investigate whether emollient application and synbiotics 
could prevent atopic dermatitis and food allergy in new-
born babies in Japan (UMIN-CTR: UMIN000010838). 
Several combinations of interventions might be effective 
to prevent allergy development.
Importance of disease prevention studies
A systematic review demonstrated that the pooled 
lifetime and point prevalence of self-reported FA was 
17.3% (95% CI 17.0–17.6) in Europe [36]. From a large-
scale birth cohort study (JECS Study), the prevalences 
of asthma, allergic rhinitis (hay fever), atopic derma-
titis, and food allergy were 10.9, 36.0, 15.7 and 4.8%, 
respectively, among 99,013 mothers in Japan [37]. In 
addition, 73.9% mothers had positive IgE sensitization. 
In 2015, the Japanese Ministry of Health, Labour and 
Welfare reported that 3 of the most common diseases 
in outpatients younger than 15 years were allergic rhi-
nitis, asthma, and atopic dermatitis [38]. In addition, a 
government report from 2013 documented a marked 
increase in food allergy in school children in Japan 
[39]. Allergic diseases are serious health concerns and 
economic burdens globaly [40]. Patients with FA often 
have a lower quality of life as a result of restrictions on 
eating causal food, which is required because of their 
high risk of developing anaphylaxis [41]. Therapeutic 
strategy to prevent allergy such as food allergy needs 
to be developed [42]. As we mentioned before, to pre-
vent future allergic march, an appropriate interven-
tion for AD, which emerges at the first stage of allergic 
march, is important to be considered. We expect that 
early aggressive intervention for AD will likely prevent 
development of later allergen sensitization, FA, asthma, 
and allergic rhinitis. If we establish a novel new strat-
egy for prevention of FA development by early aggres-
sive intervention for AD, it is expected that quality of 
life in patients will improve, the prevalence of FA will 
decrease, and the medical care cost will be reduced.
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